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Sudden cardiac death (SCD) may occur in as many as 40% of
all patients who suffer from heart failure. This review describes
the scope of the problem, risk factors for SCD, the effect of
medications used in heart failure on SCD and the potential effect
of the implantable cardioverter-defibrillator in primary preven-
tion.
(J Am Coll Cardiol 1997;30:1589–97)
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Families and physicians of ambulatory heart failure (HF)
patients have shared the grief engendered by patients who die
suddenly and unexpectedly. Sadness is compounded by frus-
tration and anger, as the patient may finally have been
“stabilized” on a medical regimen and “doing well.” With
symptomatically advancing HF, the patient, the patient’s loved
ones and the physician often change their attitude, viewing
sudden death as the most merciful mode of death. This report
reviews the current knowledge of sudden cardiac death (SCD)
in HF and strategies for primary prevention. It also considers
which patient subsets are most suitable for treatment and the
potential benefits and costs, including the financial, resource
utilization and quality-of-life ones.
It should be emphasized that the bulk of data on preventing
SCD in HF is derived from studies of secondary prevention in
patients with varying degrees of left ventricular dysfunction.
However, the stratification of functional severity has rarely
been concomitantly analyzed. As such, data on primary pre-
vention in HF populations are sparse.
Sudden Cardiac Death in HF: Scope of
the Problem
More than 2 million patients experience HF, with over
400,000 new cases annually. Many studies of patients with HF
have described the incidence of SCD in the HF population
(Table 1). In symptomatically mild HF (New York Heart
Association functional class II), the overall annual mortality is
in the range of 5% to 15%, with approximately one-half to
two-thirds being classified as sudden (1–3). In functional class
III HF, annual mortality rises to 20% to 50% (4–6), and in
class IV, it often exceeds 50% (7,8). As symptoms worsen, the
proportion of deaths that are classified as sudden decrease; in
functional class III it has been reported to be 20% to 50% and
in class IV, 5% to 30% of all deaths. Sudden cardiac death
occurs in HF from both coronary artery disease and nonisch-
emic causes, and in most but not all studies the incidence of
SCD in these two groups has been similar (6).
Causes of SCD in HF. Most studies of HF have described
the major, if not exclusive, cause of sudden death as arrhyth-
mic. In some studies a small percentage of cases of sudden
deaths (usually ,2%) are the result of nonarrhythmic causes,
such as cerebrovascular accident or pulmonary embolism. The
myopathic ventricle is extremely arrhythmogenic, which in part
may be related to mechanical factors, including chronic stretch,
remodeling and other less well understood factors (9). The
incidence of various initiating arrhythmias in SCD in HF is not
precisely known. There are a limited number of actual elec-
trocardiographic (ECG) recordings at the onset of SCD. As
such, most estimates of the initiating arrhythmia incidence are
theoretically rather than empirically based. Meissner et al. (10)
have estimated that in ischemic heart disease, monomorphic
ventricular tachycardia from structural heart disease and reen-
trant tachycardia (but not due to acute ischemia) may account
for 20% to 60% of all initiating arrhythmias, whereas polymor-
phic ventricular tachycardia or ventricular fibrillation may
account for 20% to 40% and bradyarrhythmias for ,5% to
25%. Davies’ data (11), based on pathologic examinations in
patients with ischemic heart disease dying suddenly (not
necessarily with an antecedent history of HF), have shown a
potentially anatomic basis for an ischemically mediated ar-
rhythmia in .80% of cases (occlusive thrombus in 29.8%,
mural thrombus in 43.5% and plaque fissure in only 7.7%).
Farb et al. (12) have provided similar data in a recent study.
Particularly relevant for the patient with HF is the possibility
that further myocardial necrosis, coupled with previous myo-
cardial damage, may produce enough additional pump dys-
function that if sudden death does not occur, rapidly develop-
ing myocardial failure will (Fig. 1). This point is especially
important in considering shock therapy, if prolongation of life
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is measured in days to weeks rather than months to years. Also,
if arrhythmias are primarily ischemia mediated, more aggres-
sive anti-ischemia therapy may be worthwhile in a setting
where other therapeutic modalities are typically stressed.
The initiating arrhythmia for SCD in nonischemic cardio-
myopathy is even less well documented and understood. One
frequently quoted study has suggested that up to 25% of
patients may die of a bradyarrhythmia; in this study, there were
actual precollapse ECG recordings, but they were taken on
patients admitted to the hospital and “stabilized” with severe
heart failure (13). The relevance of these data to the ambula-
tory outpatient with heart failure is unclear. Also, bundle
branch reentrant ventricular tachycardia may be somewhat
more prevalent in this group (14).
Identification of at-risk patients for SCD in HF. There are
several clinical variables that identify the patient with HF at
higher risk of dying. There are no undisputedly accepted
markers to identify the patient with HF who is most prone to
die suddenly, compared with the patient who will die from
progressive pump failure. The degree of functional impair-
ment, typically classified by the New York Heart Association
schema, is the simplest variable to predict overall survival.
Mortality rates vary somewhat between studies, but the range
of values in Table 1 reflects the consensus in the published data
and points out the major differences in survival among the
various functional classes. Although classification of symptoms
is subjective and differentiation of patients in functional class II
versus III may have a relatively high interobserver variability,
the patient with severe symptoms at rest (class IV) is unlikely
to be confused with the ambulatory patient who gets winded by
climbing one flight of stairs or by doing heavy housework. Left
ventricular dysfunction has been established as a major pre-
dictor of long-term outcome in many studies evaluating ther-
apies in coronary artery disease in patients without HF and in
secondary prevention trials of sudden death, as well as in
multiple HF studies (15–17). The combination of poor LV
function and severe functional impairment portends a worse
prognosis than either alone.
Other factors relate to worsened prognosis, particularly
when stratified in the setting of a certain functional class and
range of LV function. Nonsustained ventricular tachycardia
and complex ventricular ectopy, which increase in incidence
with worsening functional class in most studies, portend a
worse prognosis within that functional class, but for overall
mortality rather than specifically for SCD (5,18–22). In a
subgroup analysis of the Gruppo de Estudio de la Sobrevida en
la Insuficiencia Cardiaca en Argentina (GESICA) trial, non-
sustained ventricular tachycardia appeared to identify patients
with a higher propensity to have SCD as well as total mortality
(23). The level of plasma norepinephrine can be used to
stratify the risk of death (22), but it rarely is, probably because
in part of the expense and technical requirements. Further-
more, the plasma level is linked in part to functional impair-
ment and ejection fraction, although it also has some indepen-
dent predictive value (22,24). Other neurohormones, including
plasma renin activity in some but not all studies and atrial
natriuretic peptide, have been related to prognosis (25,26).
The same issues as with plasma norepinephrine have pre-
cluded wider use of these variables in clinical decision-making.
Hyponatremia (“poor man’s plasma renin activity”) has also
shown some prognostic value (27). All of these blood levels
tend to be abnormal in the most functionally impaired patient,
so they tend to separate the patient with a very bad prognosis
from a bad prognosis. Objective measures of functional im-
pairment, particularly oxygen consumption at peak exercise,
predict mortality (28). By combining an objective measure with
subjective feelings of functional impairment, a sharper risk
profile may emerge.
Direct evaluation of electrical disturbances in the dysfunc-
tional heart has provided conflicting data on the predictive
value of various tests. The signal-averaged electrocardiogram
(SAECG) in the time domain may have value in predicting
SCD in the routine post–myocardial infarction (MI) patient
(29–31); its value in patients with HF from ischemic cardio-
Figure 1. In the patient with HF from ischemic cardiomyopathy, a
small infarction may tip the balance into profound and terminal
myocardial failure if the acute ischemic event does not produce a fatal
arrhythmia. This possibility must be considered in determining a
strategy of sudden death prevention in the individual patient.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ECG 5 electrocardiographic, electrocardiogram
HF 5 heart failure
ICD 5 implantable cardioverter-defibrillator
LV 5 left ventricular
MI 5 myocardial infarction
PES 5 programmed electrical stimulation
SAECG 5 signal-averaged electrocardiogram
SCD 5 sudden cardiac death
Table 1. Sudden Death by Severity of Heart Failure Symptoms
NYHA Functional Class Annual Mortality (%) Sudden Death (%)
II 5–15 50–80
III 20–50 30–50
IV 30–70 5–30
These data summarize mortality estimates from the published data.
NYHA 5 New York Heart Association.
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myopathy is less clear (28). The SAECG does not have clear
prognostic value in patients with nonischemic cardiomyopathy
(32–36). Provocation of sustained arrhythmias, particularly
monomorphic ventricular tachycardia, by programmed electri-
cal stimulation (PES) has identified patients at higher risk for
SCD in secondary prevention studies of patients with coronary
disease (16,37–41). Patients with coronary artery disease who
have had a resuscitated SCD, syncope or documented sus-
tained monomorphic ventricular tachycardia and who have
inducible and nonsuppressible ventricular arrhythmias by class
IA agents, particularly procainamide, seem to have the worst
prognosis (37,39,41). Patients who are not inducible or “easily
suppressed” by a class Ia antiarrhythmic agent seem to have a
better prognosis (37,38). Studies evaluating groups of patients
with HF with PES as a prognostic factor are few and results are
mixed. The consensus may be summarized as follows: for
predicting SCD in patients with HF with ischemic cardiomy-
opathy, PES probably has some incremental value, although
what it may be in relation to the major determinants already
mentioned is not as clear; for patients with HF with nonisch-
emic cardiomyopathy, present PES protocols do not seem to
be predictive. We are left with the situation that the high-risk
patient can be easily determined clinically, and that more
sophisticated and expensive studies may improve risk stratifica-
tion for overall mortality.
Effect of Therapeutic Agents Used in HF on
the Incidence of SCD
Angiotensin-converting enzyme inhibitors. Substantial
data confirm the efficacy of angiotensin-converting enzyme
(ACE) inhibitors in decreasing mortality in patients with
varying degrees of functional impairment (Table 2). In addi-
tion, after a myocardial infarction (MI) patients both with and
without HF symptoms have shown a decrease in mortality with
long-term (1 to 5 years) follow-up (42–45). The effect of ACE
inhibitors on SCD is less clear. In the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS) of pa-
tients in functional class IV, ;20% of patients died suddenly,
without a difference between the enalapril and placebo groups
(7). In patients with less severe functional impairment in the
Studies of Left Ventricular Dysfunction (SOLVD) treatment
trial and in asymptomatic or minimally symptomatic patients in
the SOLVD prevention trial, there was a slight (,1%),
nonsignificant decrease in SCD (1,2). Thus, the effect of ACE
inhibitors on the prevention of SCD, although theoretically
attractive, is small in patients with established HF.
The situation is somewhat different in patients without HF
in the post-MI setting (Table 3). The Survival And Ventricular
Enlargement (SAVE) trial, which recruited patients 3 to 14
days after infarction with an ejection fraction ,35% to receive
captopril or placebo, showed a decrease of 19% in the overall
mortality rate (43). There were somewhat fewer SCDs in the
ACE inhibitor group, but the difference was not statistically
significant. The Trandolapril Cardiac Evaluation (TRACE)
trial used the ACE inhibitor trandolapril in post-MI patients
(ejection fraction ,35%) with or without mild HF (45). A
significant reduction in overall deaths, SCDs and myocardial
failure deaths was seen. Likewise, in the Survival of Myocardial
Infarction: Long-Term Evaluation (SMILE) trial using the
ACE inhibitor zofenopril in patients with an anterior MI, there
were fewer overall deaths, SCDs and HF deaths at 6 weeks in
the zofenopril compared with the placebo group (44). The
possibility of a small effect of ACE inhibitors on the prevention
of SCD is strengthened from data from the Veterans Admin-
istration Heart Failure Trial II (V-HeFT II) trial (46) compar-
ing enalapril with the combination of isosorbide dinitrate and
hydralazine. An overall reduction in mortality with enalapril
was significant at 2 years. At the end of the trial (average 2.5
years), there was still a borderline (p 5 0.08) difference in
mortality, primarily related to fewer sudden deaths with the
ACE inhibitors.
Digoxin. There has been ongoing concern that digoxin is
particularly arrhythmogenic in the setting of LV dysfunction.
Survival data are limited to the recently published Digitalis
Investigation Group (DIG) trial (47). This study compared
Table 2. Angiotensin-Converting Enzyme Inhibitors for the Prevention of Sudden Death in
Heart Failure
Study (ref. no.)
NYHA
Functional
Class
Follow-Up
(mo)
Overall
Mortality
Decrease (%) p Value
Sudden Death Mortality (%)
ACE
Inhiitors*
No ACE
Inhibitors p Value
CONSENSUS (7) IV 12 27 0.003 11.0 11.0 .0.25
(14/127) (14/126)
SOLVD RX (1) II, III 41 16 0.004 8.2 8.8 .0.25
(105/1,284) (113/1,285)
SOLVD PRE (2) I, II 37 8 0.30 4.6 5.0 0.10
(98/2,111) (105/2,117)
Overall 6.2 6.6 0.09
(217/3,522) (232/3,528)
*Enalapril was used in all studies cited. ACE 5 angiotensin-converting enzyme; CONSENSUS 5 Cooperative North
Scandinavian Enalapril Survival Study; NYHA 5 New York Heart Association; ref 5 reference; SOLVD RX and PRE 5
Studies of Left Ventricular Dysfunction, treatment and prevention, respectively.
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survival among ambulatory patients with HF (predominantly
functional classes II and III), most taking an ACE inhibitor
and a diuretic, who received either placebo or digoxin. Digoxin
had a neutral effect on survival. Interestingly, deaths classified
by the investigator as secondary to pump failure showed a
trend to decrease with digoxin, as did hospital admissions for
HF. Deaths considered “other cardiac” (presumably, in part,
SCD) were not statistically different between the two groups,
although they were somewhat higher in the digoxin group.
These findings have raised the concern that digoxin’s neutral
effect on mortality is the sum of a decrease in pump failure
deaths and a slight increase in arrhythmic deaths.
The study protocol did not provide for an independent
events committee to review the cause of death. The investiga-
tor at each site was responsible for assigning the causative
event. Even with guidelines provided to the investigators by the
study protocol, there was likely to have been significant
variations in interpretation of cause of death. Because of the
known difficulties in categorizing the cause of death, even
when analyzed rigorously, the effects of digoxin on SCD based
on the DIG data must be interpreted cautiously.
Diuretic agents. There are no data on the effect of diuretic
agents on survival in HF. This fact should not be surprising
because congestion often requires the use of diuretic agents to
maintain clinical stability. Withdrawing diuretic agents in the
stable ambulatory patient have not met with much success (48).
With these caveats in mind, diuretic agents do have the
theoretic potential to increase the risk of SCD by producing
hypokalemia and hypomagnesemia and activating the renin-
angiotensin system. Thus, a reasonable provisional strategy in
the absence of definitive clinical trial data is to minimize the
diuretic dose to a level that allows the patient to be congestion-
free as an outpatient.
Beta-adrenergic blocking agents. In post-MI studies, beta-
blockers have been shown to decrease mortality (49). The
incidence of SCD also decreases (Table 4); this effect is
particularly striking in patients with presumed or documented
LV dysfunction. The results in patients with established HF are
Table 3. Angiotensin-Converting Enzyme Inhibitors for the Prevention of Sudden Death in
Post–Myocardial Infarction Patients With Left Ventricular Dysfunction
Study (ref no.)
NYHA
Functional
Class
Follow-Up
(mo)
Overall
Mortality
Decrease (%) p Value
Sudden Death Mortality (%)
ACE
Inhibitors
No ACE
Inhibitors p Value
SAVE (43)* I 42 19 0.019 5.6 6.7 .0.25
(62/1,115) (75/1,116)
(sudden unexpected)
3.9 4.5
(43/1,115) (50/1,116)
(sudden, preceding sxs)
TRACE (45)† I, II 24–50 22 0.001 12.0 15.2 0.025
SMILE (44)‡ I, II 1.5 22 0.17 0.5 1.4 0.17
(4/772) (11/784)
Overall 7.7 9.7 0.015
(214/2,763) (269/2,773)
*Captopril. †Trandolapril. ‡Zofenopril. SAVE 5 Survival and Ventricular Enlargement; SMILE 5 Survival of
Myocardial Infarction: Long-Term Evaluation; sxs 5 symptoms; TRACE 5 Trandolapril Cardiac Evaluation; other
abbreviations as in Table 2.
Table 4. Beta-Blockers for Prevention of Sudden Death After
Myocardial Infarction and Heart Failure
Trial
NYHA
Functional
Class
Sudden Death Mortality (%)
BB No BB p Value
After MI
BHAT, hx CHF
Yes II 5.5 10.4 ,0.05
(19/345) (38/365)
No I 2.9 3.4 NS
(45/1,541) (53/1,556)
Timolol, heart size
Normal 5.1 7.3 NS
(31/608) (43/591)
Borderline 6.9 13.7 NS
(9/131) (18/131)
Enlarged 12.9 22.7 ,0.05
(26/202) (49/216)
Heart failure
MDC II, III 9.8 6.3 NS
(18/184) (12/189)
CIBIS III, IV 4.9 5.3 NS
(15/320) (17/321)
Carvedilol II, III 1.7 3.8 ,0.01
(12/696) (15/398)
BB 5 beta-blockers; BHAT 5 Beta-Blocker Heart Attack Trial; CHF 5
congestive heart failure; CIBIS 5 Cardiac Insufficiency Bisoprolol Study; hx 5
history of; MDC 5 Metoprolol in Dilated Cardiomyopathy trial; MI 5 myocar-
dial infarction; NYHA 5 New York Heart Association.
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therefore somewhat paradoxic. In the Metoprolol in Dilated
Cardiomyopathy (MDC) trial (50) using metoprolol in patients
with noncoronary cardiomyopathy, SCD was not decreased,
nor was it significantly decreased in the Cardiac Insufficiency B
Isoprolol Study (CIBIS) (not powered as a mortality trial) (51).
In contrast, the combination of three trials using carvedilol in
patients with mostly mild to moderate HF showed a significant
reduction in all-cause, heart failure, and SCD mortality rates
(52). The ongoing Beta-Blocker Evaluation of Survival Trial
(BEST) survival trial using bucindolol may further clarify the
value of beta-blockers in preventing SCD.
Calcium channel blockers. Studies with the first-generation
dihydropyridines, verapamil and diltiazem, have failed to show
survival benefit in the setting of HF or LV dysfunction, or both,
and in some cases, worsening (53–55). The second-generation,
“vascular-specific” dihydropyridine, amlodipine, has been
subjected to a placebo-controlled survival trial (Prospective
Randomized Amlodipine Survival Evaluation [PRAISE]) in
patients with ischemic and nonischemic cardiomyopathy (56).
Overall, survival rates were similar for amlodipine- and placebo-
treated groups, with an improved survival in the nonischemic
cardimyopathy group. The reason for the decrease in deaths in
this subgroup has not been described to date. These data have
prompted PRAISE II, a survival study limited to a nonischemic
cardiomyopathy cohort.
Antiarrhythmic agents. No class I antiarrhythmic agent has
shown evidence of preventing SCD in HF (or in any other
setting). It is unlikely that such a trial will proceed because of
the propensity for proarrhythmia in this class of antiarrhythmic
agents in patients with LV dysfunction and HF and the results
of the Cardiac Arrhythmia Suppression Trials (CAST) I and II
(57,58). These trials addressed primary prevention of SCD in
patients after they had an MI with ventricular ectopy and in
most cases LV dysfunction. The active drug arms, either
encainide or flecainide, demonstrated a significant increase in
mortality compared with placebo (57), whereas moricizine
showed a nonsignificant increase in mortality (58). The in-
crease in mortality was seen for both SCD and non-SCD,
suggesting a more widespread deleterious effect of these
agents, rather than a proarrhythmogenic effect only.
These data may be contrasted with the results with amio-
darone. No study in post-MI patients has shown an increase in
mortality and some have shown a decrease (59–64). Results of
primary sudden death prevention in HF have been mixed. The
American Congestive Heart Failure–Survival Trial of Antiar-
rhythmic Therapy (CHF-STAT) (;40% mortality at 2 years)
showed no difference in mortality between amiodarone and
placebo, with ;50% of the deaths being sudden (65). In this
study, patients with nonischemic cardiomyopathy showed a
trend toward improved survival, but the causes of death were
not reported in this subgroup analysis. The Argentinian
GESICA trial (66) did show a significant mortality reduction
with amiodarone (overall risk reduction 27% over 2 years).
Two-thirds of the study patients had nonischemic cardiomyop-
athy. The decrease in mortality was due to a decrease in both
SCD and pump failure deaths, suggesting that amiodarone, in
contrast to the class I agents tested in CAST, had salutary
actions in addition to its antiarrhythmic effect. More recently,
in two large randomized trials of amiodarone after MI, there
was a significant reduction in SCD (;35%) but no reduction in
overall mortality (62,63). This somewhat perplexing result may
be related to problems in death classification or, more omi-
nously, a deleterious component of amidarone (64). In the
latter regard, the recently published Survival With Oral D-
Sotalol (SWORD) trial comparing the class III agent D-sotalol
with placebo in post-MI patients also showed a significant
increase in mortality with the active agent (67).
Implantable Cardioverter-Defibrillator
There is much enthusiasm that the implantable cardioverter-
defibrillator (ICD) can prevent SCD in HF (68,69). This
attitude is aptly stated in a recent editorial: “The real and
legitimate question concerning ICD therapy is no longer ‘Do
ICDs prolong life?’ but rather ‘Which patients benefit most?’
and ‘What is the cost effectiveness of the ICD in the prevention
of sudden death and prolongation of life?’ ” (69). The remain-
der of this report will address these issues as they relate to the
patient with HF.
First, it must be admitted, even by the most enthusiastic
advocate of ICD therapy, that scientific data for ICD use in
primary prevention in the setting of HF are not available. Data
used to suggest that the ICD saves lives include studies in
patients who have had a cardiac arrest or syncope (secondary
prevention) (16,70,71), studies using historic control subjects
(72) and studies in which LV function but not functional
impairment from HF has been characterized (16,68). Pub-
lished survival results have not uniformly favored the ICD
(73–75). For example, in one study of SCD survivors with an ICD
who had no inducible arrhythmias by PES, the SCD-free interval
was significantly prolonged but overall survival was not (74).
There are reasons to be concerned that the benefit from an
ICD in the HF setting may indeed be limited. The primary
reason is that a large percentage of deaths from myocardial
failure may be expected over time (ranging from 4% to 50%
per year depending on the severity of symptoms). In a study of
patients awaiting heart transplant, the majority of deaths
(approximately two-thirds) were nonsudden (75). Although
SCD was significantly decreased, overall mortality was not.
Second, in all ICD studies, SCD continues to occur (typical 1%
to 2% per year in patients who do not have HF). If we
hypothesize that some of these deaths are ischemic with
further myocardial necrosis, salvage from SCD may, within a
short period of time, convert the patient to a pump failure
death. The issue of operative mortality has fortunately been
avoided by the use of transvenous devices, particularly for
patients with a very dilated, structurally deranged heart (76).
We may consider a “best case” scenario for ICD therapy
constructed from the published data as follows: in functional
class II, mortality will be decreased by 50% of its baseline; class
III, 30% of its baseline; and class IV, 8%. Because the annual
mortality of functional class III is much higher than class II,
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more patients will actually be saved from SCD if a general
strategy of implanting ICDs is targeted for this group. How-
ever, many more patients in this class will progress to terminal
HF and the patient will be defibrillated by the device in the
throes of terminal pump failure or the physician will prepare
for the terminal event by deactivating the device. Applying a
general strategy may indeed save lives if applied to less
functionally limited patients (class II), but fewer patients may
be expected to use the device. Figure 2 illustrates the potential
life-saving effects of placing an ICD solely on the basis of
functional class. In theory, the ICD could provide an improve-
ment in long-term survival comparable or superior to agents
that have been shown to improve survival in HF, particularly
ACE inhibitors.
If trial data are forthcoming in support of the use of the
ICD for primary prevention, then the question will emerge
whether we can afford such a strategy. Actual study data are
required to answer this question; a first-order approximation of
costs may estimate the cost of each life-year saved. These
assumptions are the “best case” scenario for ICD costs.
Assumptions include an annual mortality rate of 8% in func-
tional class II, with 50% of these deaths being sudden and
preventable, and an annual mortality of 30% in functional class
III, with 30% of these deaths being sudden and preventable.
Furthermore, we assume that all SCDs can be prevented and
that SCD in the HF group costs no money to treat (i.e., no
resuscitative efforts, hospital admissions). The incremental
costs of the ICD are considered limited to implantation and
follow-up costs, and all ICDs perform flawlessly without the
need for a battery change for 5 years. We also assume that
there are no implantation deaths or morbidity, that the average
hospital stay is #3 days, that no electrophysiologic testing is
performed and that no new antiarrhythmic drugs are used after
implantation. Finally, we assume a cost for ICD placement and
follow-up of $40,000 over an approximate period of 5 years
(77).
Applying this model to 100 patients followed for 5 years, 30
life-years will be saved in patients in functional class II and 65
life-years in those in class III. The cost per life-year saved will
be approximately $133,000 for patients in functional class II
and $62,000 for those in class III. Owens et al. (78), using a
sophisticated Markovian model comparing the incremental
cost of ICD with amiodarone in SCD survivors, concluded a
somewhat similar cost for ICD per life-year saved (average
cost approximately $74,000). In the high risk group in the
Multicenter Automatic Defibrillator Implantation Trial
(MADIT), a preliminary report has suggested that the cost per
life-year saved ranged from $23,000 to $38,000 based on the
statistical model used (77). These results demonstrate that
costs are sensitive to the patient’s mortality risk and that ICD
therapy applied on a large scale is likely to be an expensive
approach for society as a whole.
How expensive will this be compared with other life-saving
therapies? It has been estimated that the incremental cost per
life-year saved for outpatient dialysis is approximately $40,000
to $60,000 (79); that of the thrombolytic agent streptokinase as
compared with placebo is estimated to be $3,500 to $21,000;
and that of tissue-type plasminogen activator over streptoki-
nase is $16,000 to $60,000 (80,81). It has recently been
reported that primary prevention of coronary events with the
hepatic hydroxymethyl glutaryl coenzyme A reductase inhibi-
tor pravastatin costs in the range of $15,000 to $30,000 per
life-year saved (82). Thus, ICD placement for all, although
life-saving in patients of a certain functional class, will be an
expensive strategy. It will then become a societal question if
this strategy is worth the money.
Two presently ongoing or imminent studies are addressing
primary SCD prevention in HF. One is the German-Austrian
CArdiomyopathy Trial (CAT) (83,84). The primary study
group is limited to patients with nonischemic cardiomyopathy
with an assumed mortality rate of 30%, and 40% of that
mortality rate is assumed to be sudden, which is a predicted
absolute reduction in mortality of 6% in the ICD arm with a
follow-up time of 1 year. That trial assumes that there will be
almost complete elimination of SCD and that there will be
significant operative mortality from thoracotomy-placed ICD
(21% of all ICD deaths). Although the use of the transvenous
approach will decrease mortality in the ICD arm, the assump-
tion that 40% of deaths will be SCD in this group, in order to
reach statistical significance, may be too optimistic, because
many studies have shown fewer SCDs when the yearly overall
mortality rate is as high as 30%. The other major study is the
Sudden Cardiac Death in Heart Failure: Trial of prophylactic
amiodarone versus implantable defibrillator therapy (SCD-
HeFT) study, which uses the strategy of ICD placement in
ambulatory patients with HF (85). It is a three-arm trial:
“optimal” medical therapy alone; optimal medical therapy and
amiodarone; and medical therapy and ICD. The sample size
(n 5 2,500) assumes a 25% annual mortality rate in the
Figure 2. This figure shows the potential of the ICD to prolong life in
patients in functional class II or III. It assumes that the yearly mortality
rate in functional class II is 8% and that the sudden death percentage
is 50% in this class. It also assumes an annual mortality rate in functional
class III of 30% and that 30% of all deaths are sudden. Finally, it assumes
that the ICD can prevent all sudden deaths (refer to text).
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medical therapy alone arm and a mortality reduction of 20% in
the ICD arm. The SCD rate of 20% to 25% and the longer
follow-up of 2 to 3 years in SCD-HeFT provide a somewhat
better opportunity to find a difference than in CAT.
The recently published MADIT trial (41) showed that in a
highly selected high risk post-MI group, primary prevention of
SCD could be achieved (with a risk reduction of 54% over an
average of 27 months) (Fig. 3A). This study, by design, tried to
recruit a very high risk patient group by using post-MI patients
with severe LV dysfunction (ejection fraction ,35%) and
nonsustained ventricular tachycardia on Holter monitoring
(note that these two variables are risk factors for increased
mortality in patients within any functional class). Patients were
then further stratified according to their inducibility by PES
and their suppressibility with procainamide. This study was not
a primary prevention in HF trial. Nevertheless, valuable in-
sights may be gleaned from this study in that the patient group
was very similar to an average HF group. Two-thirds of the
patient group had a history of HF with either functional class
II or III symptoms; over half of the patients were taking an
ACE inhibitor and a diuretic agent; and ;40% to 50% were
taking digoxin. Based on the percentage of the patients in
functional classes I, II and III (86) and the mortality assump-
tions used for Figure 2, we may calculate 5-year mortality on
the basis of HF symptoms alone (Fig. 3B). The actual higher
mortality seen in the non-ICD group represents the successful
selection process of recruiting very high risk patients for SCD.
Although screening with PES is formidable and possibly
prohibitive, the MADIT trial points out that a very high risk
group can be obtained, which may in turn help to maximize the
life-saving potential of the ICD (38).
The ICD as an initial treatment for secondary prevention of
SCD in patients with severe symptomatic ventricular arrhyth-
mias (very high risk group) has been shown in the National
Heart, Lung and Blood Institute–sponsored Antiarrhythmics
Vs Implantable Defibrillators (AVID) trial to decrease overall
mortality in comparison with antiarrhythmic therapy (87). This
study, which was discontinued early because of the favorable
effect of ICD on mortality, showed a 38% reduction at 1 year
and a 25% reduction at 2 and 3 years in comparison with
amiodarone or sotalol (87). There are two ongoing random-
ized clinical trials comparing ICD with amiodarone therapy in
patients who have survived an episode of SCD (Cardiac Arrest
Study Hamburg [CASH]) or had hemodynamically unstable
sustained ventricular tachycardia (Canadian Implantable De-
fibrillator Study [CIDS]) (88,89). The AVID data and the
anticipated results of the CASH and CIDS will likely increase
the momentum to consider ICD use for primary prevention in
patients with HF, although the risk-benefit ratio is at present
unknown.
Conclusions. Data from studies on pharmacologic therapy
suggest that the greatest benefit in preventing SCD occurs in
patients with LV dysfunction with at most mild to moderate
symptoms. As functional impairment increases, drugs become
less effective. Angiotensin-converting enzyme inhibitors pro-
vide only modest, if any, protection against SCD in patients
with established HF. In patients with asymptomatic LV dys-
function after MI, a small benefit in decreasing SCD may be
present. No data support the proposition that digoxin or
diuretic agents decrease SCD, and hypothetically may increase
it, although data are insufficient to support this either. The
possibility that beta-blockers and amiodarone decrease the risk
of SCD is supported by some but not all data.
Although several arrhythmic markers of SCD can be iden-
tified, the results of antiarrhythmic therapy aimed at primary
prevention of SCD have been disappointing.
The most encouraging prospect, at present, for preventing
sudden death is the transvenous ICD, where technologic
advances have been remarkable. The generator size and
technology of the ICD allow for a minimally invasive proce-
dure and in many cases a brief (,24 h) hospital stay. These
improvements will reduce the costs per implantation. The
developments of electrogram storage and retrieval and remote
ICD interrogation will further reduce the costs of ICD man-
agement. Recently approved ICD devices have expected bat-
tery longevity of .7 years. With the increasing number of ICD
placements, it is anticipated that unit costs will decrease. All of
these changes will decrease the cost per life-year saved.
Figure 3. A, Results of the MADIT trial. B, Superimposition of the
expected mortality in the conventional arm based on functional class
alone, assuming an annual mortality rate of 4% in functional class I,
8% in class II and 30% in class III, or an annual aggregate mortality
rate of 14% (refer to text).
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Furthermore, interrogating electrograms before shocking will
further our understanding of the initiating arrhythmias of
SCD, including the role of bradyarrhythmias. In addition,
current devices have bradycardia pacing capabilities. Newer
devices with dual-chamber pacing capabilities will soon be
approved.
Similar to data from pharmacologic trials, secondary ICD
prevention studies suggest that less functionally impaired
patients with HF will have the greatest gain in overall survival
from prophylactic ICD placement. This fact underscores the
importance of developing a more exact risk profile for SCD in
this large group of patients.
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